Land: Vereinigtes Königreich
Sprache: Englisch
Quelle: VMD (Veterinary Medicines Directorate)
Clindamycin
Vetoquinol UK Ltd
QJ01FF01
Clindamycin
Tablet
POM-V - Prescription Only Medicine – Veterinarian
Dogs
Antimicrobial
Expired
2010-09-08
Revised: June 2015 AN 01673/2014 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Clindacyl 300 mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Clindamycin (as Clindamycin Hydrochloride) 300 mg EXCIPIENTS: For the full list of excipients, see section 6.1 3. PHARMACEUTICAL FORM Tablet White round tablet with a breakline on one side 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Clindacyl 300 mg Tablets are indicated for the treatment of infected wounds, abscesses, superficial pyoderma and oral cavity/dental infections caused by or associated with clindamycin-sensitive staphylococci, streptococci, bacteroidaceae, _Fusobacterium necrophorum_, _ Clostridium perfringens_ and osteomyelitis caused by _Staphylococcus aureus_. Clindacyl 300 mg Tablets can also be used to help provide antimicrobial cover during dental procedures. 4.3 CONTRAINDICATIONS Do not administer to animals with hypersensitivity to clindamycin or any excipients or to lincomycin preparations. Do not administer to rabbits, guinea pigs, chinchillas, hamsters, horses or ruminants. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Before the use of Clindacyl 300 mg tablets, the identification of causative pathogenic micro-organisms should be carried out and the sensitivity to clindamycin should be Revised: June 2015 AN 01673/2014 Page 2 of 6 established. Clindamycin and lincomycin show parallel resistance. There is a partial cross-resistance to erythromycin and other macrolide antibiotics. 4.5 SPECIAL PRECAUTIONS FOR USE SPECIAL PRECAUTIONS FOR USE IN ANIMALS During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed. Patients with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high dose clindamycin therapy. OFFICIAL AND Lesen Sie das vollständige Dokument